BG104192A - Substituted 4-oxo-naphthyridine-3-carboxamides as gaba brain receptor ligands - Google Patents

Substituted 4-oxo-naphthyridine-3-carboxamides as gaba brain receptor ligands

Info

Publication number
BG104192A
BG104192A BG104192A BG10419200A BG104192A BG 104192 A BG104192 A BG 104192A BG 104192 A BG104192 A BG 104192A BG 10419200 A BG10419200 A BG 10419200A BG 104192 A BG104192 A BG 104192A
Authority
BG
Bulgaria
Prior art keywords
substituted
carboxamides
naphthyridine
oxo
agonists
Prior art date
Application number
BG104192A
Other languages
Bulgarian (bg)
Inventor
Pamela Albaugh
Robert Desimone
Gang Liu
Original Assignee
Neurogen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corporation filed Critical Neurogen Corporation
Publication of BG104192A publication Critical patent/BG104192A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention encompasses structures or the pharmaceutically acceptable non-toxic salts thereof of formula wherein: X is hydrogen, halogen, (un)substituted alkyl, (un)substituted alkoxy or amino; and Y is (un)substituted alkyl, aryl, or heteroaryl, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness. 105 claims
BG104192A 1997-08-25 2000-02-25 Substituted 4-oxo-naphthyridine-3-carboxamides as gaba brain receptor ligands BG104192A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91818097A 1997-08-25 1997-08-25
PCT/US1998/017513 WO1999010347A1 (en) 1997-08-25 1998-08-24 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Publications (1)

Publication Number Publication Date
BG104192A true BG104192A (en) 2001-05-31

Family

ID=25439933

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104192A BG104192A (en) 1997-08-25 2000-02-25 Substituted 4-oxo-naphthyridine-3-carboxamides as gaba brain receptor ligands

Country Status (24)

Country Link
EP (1) EP1007526A1 (en)
JP (1) JP2001514181A (en)
KR (1) KR20010023313A (en)
CN (1) CN1268136A (en)
AP (1) AP2000001742A0 (en)
AU (1) AU753800B2 (en)
BG (1) BG104192A (en)
BR (1) BR9811362A (en)
CA (1) CA2301599C (en)
EG (1) EG21717A (en)
HU (1) HUP0003258A3 (en)
IL (1) IL134291A0 (en)
IS (1) IS5382A (en)
LV (1) LV12539B (en)
NO (1) NO20000822L (en)
NZ (1) NZ502548A (en)
OA (1) OA11293A (en)
PE (1) PE130999A1 (en)
PL (1) PL338783A1 (en)
SI (1) SI20270A (en)
SK (1) SK2162000A3 (en)
TW (1) TW574221B (en)
WO (1) WO1999010347A1 (en)
YU (1) YU10500A (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE289593T1 (en) * 1999-05-06 2005-03-15 Neurogen Corp SUBSTITUTED 4-OXO-QUINOLINE-3-CARBOXAMIDE AS GABA BRAIN RECEPTOR LIGANDS
US6448246B1 (en) 1999-05-25 2002-09-10 Neurogen Corporation Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
ES2274913T3 (en) 2000-10-12 2007-06-01 MERCK & CO., INC. AZA AND POLIAZA-NAFTALENIL CARBOXAMIDS USEFUL AS INTEGRATED HIV INHIBITORS.
WO2002030426A1 (en) 2000-10-12 2002-04-18 Merck & Co., Inc. Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
CZ20031028A3 (en) 2000-10-12 2003-08-13 Merck & Co., Inc. Aza- and polyazanaphthalenyl carboxamides
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
CN1494422A (en) * 2001-03-01 2004-05-05 �Ʒ� Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for treatment of cognitive disorders
AR036256A1 (en) 2001-08-17 2004-08-25 Merck & Co Inc SODIUM SALT OF AN HIV INTEGRAS INHIBITOR, PROCESSES FOR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
JP4523281B2 (en) 2002-01-17 2010-08-11 メルク・シャープ・エンド・ドーム・コーポレイション Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
AU2003218130A1 (en) 2002-03-15 2003-09-29 Merck And Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
WO2004106336A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Process for the preparation and purification of 1,5-naphthyridine-3-carboxyamides
WO2004106334A2 (en) * 2003-05-28 2004-12-09 Pfizer Products Inc. Process for the preparation of 1,5-naphthyridine-3-carboxy amides by direct ester amidation
PT2074123E (en) * 2006-10-16 2013-01-22 Bionomics Ltd Novel anxiolytic compounds
JP2010510314A (en) * 2006-11-22 2010-04-02 シーサイド セラピューティクス，エルエルシー Method for treating mental retardation, Down syndrome, fragile X syndrome and autism

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR204162A1 (en) * 1972-05-08 1975-11-28 Yamanouchi Pharma Co Ltd PROCESS FOR THE PREPARATION OF AMPICILLIN DERIVATIVES
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
US4374138A (en) * 1981-11-13 1983-02-15 Warner-Lambert Company Antibacterial amide compounds, compositions, and methods of use
DD279887A1 (en) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun METHOD OF PREPARING D-ALPHA- (4 (1H) -1,5-NAPHTHYRIDONE-3-CARBOXAMIDO) -BENZYLPENICILLIN AND OTHER BETA LACTAMANTIBIOTICS
DD279875A1 (en) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun PROCESS FOR PREPARING ACTIVATED CARBONIC ACID ESTERS
DD295360A5 (en) * 1987-07-03 1991-10-31 Akad Wissenschaften Process for the preparation of activated carboxylic acid esters
JPS6461461A (en) * 1987-09-01 1989-03-08 Otsuka Pharma Co Ltd Benzohetero ring derivative

Also Published As

Publication number Publication date
AP2000001742A0 (en) 2000-02-24
CA2301599A1 (en) 1999-03-04
SK2162000A3 (en) 2001-03-12
IS5382A (en) 2000-02-22
HUP0003258A2 (en) 2001-03-28
EG21717A (en) 2002-02-27
CA2301599C (en) 2003-03-25
PE130999A1 (en) 1999-12-16
IL134291A0 (en) 2001-04-30
HUP0003258A3 (en) 2001-05-28
AU753800B2 (en) 2002-10-31
LV12539A (en) 2000-10-20
SI20270A (en) 2000-12-31
AU9117398A (en) 1999-03-16
NO20000822L (en) 2000-04-13
BR9811362A (en) 2000-08-22
YU10500A (en) 2002-10-18
KR20010023313A (en) 2001-03-26
PL338783A1 (en) 2000-11-20
WO1999010347A1 (en) 1999-03-04
NO20000822D0 (en) 2000-02-18
CN1268136A (en) 2000-09-27
EP1007526A1 (en) 2000-06-14
LV12539B (en) 2001-01-20
OA11293A (en) 2002-11-19
NZ502548A (en) 2002-06-28
TW574221B (en) 2004-02-01
JP2001514181A (en) 2001-09-11

Similar Documents

Publication Publication Date Title
BG104192A (en) Substituted 4-oxo-naphthyridine-3-carboxamides as gaba brain receptor ligands
OA09579A (en) Certain imidazoquinoxalines a new class of gaba brain receptor ligands
CA2175204A1 (en) Certain Fused Pyrrolecarboxanilides; a New Class of GABA Brain Receptor Ligands
NZ330861A (en) Fused pyrrolecarboxamides and use as a new class of GABA brain receptor ligands
AU4818000A (en) Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
NO20013001L (en) 2,3,4,4A-tetrahydro-1H-pyrazino (1,2-A) quinoxaline-5 (6H) one derivatives which are 5HT2C agonists
DE60106641D1 (en) CYCLOPENTA [B] [1,4] DIAZEPINO [6,7,1-HI] INDOLE AS 5HT2C ANTAGONISTS
TW200510324A (en) 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
WO2002000623A3 (en) Aryl fused substituted 4-oxy-pyridines
WO1999043661A3 (en) Substituted cycloalkyl-4-oxonicotinic carboxamides; gaba brain receptor ligands
AU2321597A (en) Novel imidazo{1,5-c}quinazolines; a new class of gaba brain receptor ligands
DE60014339T8 (en) ARYL AND HETEROARYL-CONDENSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAA RECEPTORS
AP2002002420A0 (en) Fused pyrrolecarboxamides: gaba brain receptor ligands.
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
CA2223936A1 (en) Novel substituted aryl and cycloalkyl imidazolones; a new class of gaba brain receptor ligands
DE69926378D1 (en) OXO-PYRIDOIMIDAZOLE-CARBOXAMIDE: GABA RECEPTOR LIGANDS IN THE BRAIN
CA2249562A1 (en) Certain fused pyrrolecarboxamides as gaba brain receptor ligands
MY107732A (en) Certain imidazoquinoxalines; a new class of gaba brain receptor ligands.
DE69907448D1 (en) PYRIDO [2,3-B] INDOLICINE DERIVATIVES AND AZA ANALOGS: CRF1 SPECIFIC LIGANDS
MX9709771A (en) Novel substituted aryl and cycloalkyl imidazolones; a new class of gaba brain receptor ligands.
AR007742A1 (en) FUSIONED PYROLCARBOXANILIDES; A NEW KIND OF LIGAND GABA BRAIN RECEPTORS.
BG96204A (en) IMIDAZOQUINOXALINES, A NEW CLASS OF GAVA BRAIN RECEPTOR LIGANDS